Medical Market Report

Global Celiac Disease Drug Market By Type (Distension, Diarrhea, and Anorexia), By Application (First line of treatment, and Second line of treatment), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 138259
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global Celiac Disease Drug Market is estimated to be valued US$ XX.X million in 2019. The report on Celiac Disease Drug Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global celiac disease drug market is segmented on the basis of Type, Application, and geography.

    Europe market was valued at US$ XX.X million in 2018 and is projected to reach US$ XX.X million in 2029, and register a CAGR of X.X% during the forecast period, according to a new Market.us (Prudour Research) study.

    Celiac Disease Drug Market Scope:

    By type, the market is segmented into Distension, Diarrhea, and Anorexia. By Application, the market is divided into First line of treatment, and Second line of treatment.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include F. Hoffmann-La Roche, Johnson & Johnson, Merck, Pfizer, ADMA Biologics, Amgen, Anthera Pharmaceuticals, Bayer, Biogen, BioLineRx, Biotest, Bristol-Myers Squibb, Celgene, Takeda Pharmaceutical, Novartis, LFB Group, and Kedrion Biopharma.

    Key Market Segments

    Type

    Distension

    Diarrhea

    Anorexia

    Application

    First line of treatment

    Second line of treatment

    Key Market Players included in the report:

    F. Hoffmann-La Roche

    Johnson & Johnson

    Merck

    Pfizer

    ADMA Biologics

    Amgen

    Anthera Pharmaceuticals

    Bayer

    Biogen

    BioLineRx

    Biotest

    Bristol-Myers Squibb

    Celgene

    Takeda Pharmaceutical

    Novartis

    LFB Group

    Kedrion Biopharma

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Celiac Disease Drug Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Celiac Disease Drug Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Celiac Disease Drug Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Celiac Disease Drug Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Celiac Disease Drug Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Celiac Disease Drug Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Celiac Disease Drug sub-markets, depending on key regions (various vital states).
    To analyze Celiac Disease Drug Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Celiac Disease Drug Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide Celiac Disease Drug Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Celiac Disease Drug Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope
    

    2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players
    

    3. Global Celiac Disease Drug Market Overview
    

    3.1. Celiac Disease Drug Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
    

      3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy
    

    4. Global Celiac Disease Drug Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Celiac Disease Drug Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Distension
    

      4.4. Diarrhea
    

      4.5. Anorexia
    

    5. Global Celiac Disease Drug Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Celiac Disease Drug Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. First line of treatment
    

      5.4. Second line of treatment
    

    6. Global Celiac Disease Drug Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Celiac Disease Drug Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Celiac Disease Drug Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Celiac Disease Drug Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Celiac Disease Drug Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Celiac Disease Drug Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    

    7. Global Celiac Disease Drug Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. F. Hoffmann-La Roche
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
    

      7.4. Johnson & Johnson
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
    

      7.5. Merck
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
    

      7.6. Pfizer
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
    

      7.7. ADMA Biologics
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
    

      7.8. Amgen
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
    

      7.9. Anthera Pharmaceuticals
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
    

      7.10. Bayer
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
    

      7.11. Biogen
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
    

      7.12. BioLineRx
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

      7.13. Biotest
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
    

      7.14. Bristol-Myers Squibb
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments
    

      7.15. Celgene
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments
    

      7.16. Takeda Pharmaceutical
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments
    

      7.17. Novartis
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments
    

      7.18. LFB Group
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments
    

      7.19. Kedrion Biopharma
    

        7.19.1. Company Overview
    
    7.19.2. Financial Highlights
    
    7.19.3. Product Portfolio
    
    7.19.4. SWOT Analysis
    
    7.19.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.